Requirement for CDK6 in MLL-rearranged acute myeloid leukemia

Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1

Barbie, D. A., Tamayo, P., Boehm, J. S., Kim, S. Y., Moody, S. E., Dunn, I. F., Schinzel, A. C., Sandy, P., Meylan, E., Scholl, C., et al. (2009) · Nature · doi:10.1038/nature08460 · Cited by 3,922

Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet

Döhner, H., Estey, E. H., Amadori, S., Appelbaum, F. R., Büchner, T., Burnett, A. K., Dombret, H., Fenaux, P., Grimwade, D. J., Larson, R. A., et al. (2009) · Blood · doi:10.1182/blood-2009-07-235358 · Cited by 3,438

Distinct Sets of Genetic Alterations in Melanoma

Curtin, J. A., Fridlyand, J., Kageshita, T., Patel, H. N., Busam, K. J., Kutzner, H., Cho, K.-H., Aiba, S., Bröcker, E.-B., LeBoit, P. E., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050092 · Cited by 2,747

Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials

Grimwade, D. J., Hills, R. K., Moorman, A. V., Walker, H., Chatters, S., Goldstone, A. H., Wheatley, K., Harrison, C. J., & Burnett, A. K. (2010) · Blood · doi:10.1182/blood-2009-11-254441 · Cited by 1,936

RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia

Zuber, J., Shi, J., Wang, E., Rappaport, A. R., Herrmann, H., Sison, E. A., Magoon, D., Qi, J., Blatt, K., Wunderlich, M., et al. (2011) · Nature · doi:10.1038/nature10334 · Cited by 1,870

Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia

Dawson, M. A., Prinjha, R. K., Dittmann, A., Giotopoulos, G., Bantscheff, M., Chan, W.-I., Robson, S. C., Chung, C., Hopf, C., Savitski, M. M., et al. (2011) · Nature · doi:10.1038/nature10509 · Cited by 1,530

Transformation from committed progenitor to leukaemia stem cell initiated by MLL–AF9

Krivtsov, A. V., Twomey, D., Feng, Z., Stubbs, M. C., Wang, Y., Faber, J., Levine, J. E., Wang, J., Hahn, W. C., Gilliland, D. G., et al. (2006) · Nature · doi:10.1038/nature04980 · Cited by 1,513 · cited 1×

A p16 INK4a -Insensitive CDK4 Mutant Targeted by Cytolytic T Lymphocytes in a Human Melanoma

Wölfel, T., Hauer, M., Schneider, J., Serrano, M., Wölfel, C., Klehmann, E., Plaen, E. D., Hankeln, T., Büschenfelde, K. M. Z., & Beach, D. (1995) · Science · doi:10.1126/science.7652577 · Cited by 1,171

Selective Killing of Mixed Lineage Leukemia Cells by a Potent Small-Molecule DOT1L Inhibitor

Daigle, S. R., Olhava, E. J., Therkelsen, C. A., Majer, C. R., Sneeringer, C. J., Song, J. J., Johnston, L. D., Scott, M. P., Smith, J. J., Xiao, Y., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.06.009 · Cited by 926

MLL-Rearranged Leukemia Is Dependent on Aberrant H3K79 Methylation by DOT1L

Bernt, K. M., Zhu, N., Sinha, A. U., Vempati, S., Faber, J., Krivtsov, A. V., Feng, Z., Punt, N., Kedaigle, A. J., Bullinger, L., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.06.010 · Cited by 872

Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel

Döhner, H., Estey, E. H., Grimwade, D. J., Amadori, S., Appelbaum, F. R., Büchner, T., Dombret, H., Ebert, B. L., Fenaux, P., Larson, R. A., et al. (2016) · Blood · doi:10.1182/blood-2016-08-733196 · Cited by 5,938

Genomics of Acute Myeloid Leukemia Diagnosis and Pathways

Bullinger, L., Döhner, K., & Döhner, H. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.71.2208 · Cited by 570

Quality control, modeling, and visualization of CRISPR screens with MAGeCK-VISPR

Li, W., Köster, J., Xu, H., Chen, C.-H., Xiao, T., Liu, J. S., Brown, M. A., & Liu, X. S. (2015) · Genome biology · doi:10.1186/s13059-015-0843-6 · Cited by 503

A Menin-MLL Inhibitor Induces Specific Chromatin Changes and Eradicates Disease in Models of MLL-Rearranged Leukemia

Krivtsov, A. V., Evans, K., Gadrey, J. Y., Eschle, B. K., Hatton, C., Uckelmann, H. J., Ross, K. N., Perner, F., Olsen, S. N., Pritchard, T., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.11.001 · Cited by 460

Molecular landscape of acute myeloid leukemia in younger adults and its clinical relevance

Grimwade, D. J., Ivey, A., & Huntly, B. J. P. (2015) · Blood · doi:10.1182/blood-2015-07-604496 · Cited by 475

MLL-Rearranged Leukemias—An Update on Science and Clinical Approaches

Winters, A. C., & Bernt, K. M. (2017) · Frontiers in Pediatrics · doi:10.3389/fped.2017.00004 · Cited by 402

CDK6 Levels Regulate Quiescence Exit in Human Hematopoietic Stem Cells

Laurenti, E., Frelin, C., Xie, S. Z.-J., Ferrari, R., Dunant, C. F., Zandi, S., Neumann, A. L., Plumb, I., Doulatov, S. R., Chen, J., et al. (2015) · Cell stem cell · doi:10.1016/j.stem.2015.01.017 · Cited by 339

Cyclin-dependent protein kinases and cell cycle regulation in biology and disease

Pellarin, I., Dall’Acqua, A., Favero, A., Segatto, I., Rossi, V., Crestan, N., Karimbayli, J., Belletti, B., & Baldassarre, G. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02080-z · Cited by 381

How I treat refractory and early relapsed acute myeloid leukemia

Thol, F. R., Schlenk, R. F., Heuser, M., & Ganser, A. (2015) · Blood · doi:10.1182/blood-2014-10-551911 · Cited by 307

CDK6 as a key regulator of hematopoietic and leukemic stem cell activation

Scheicher, R., Hoelbl‐Kovacic, A., Bellutti, F., Tigan, A.-S., Prchal‐Murphy, M., Heller, G., Schneckenleithner, C., Salazar‐Roa, M., Zöchbauer‐Müller, S., Zuber, J. A., et al. (2014) · Blood · doi:10.1182/blood-2014-06-584417 · Cited by 265

CDK6—a review of the past and a glimpse into the future: from cell-cycle control to transcriptional regulation

Tigan, A.-S., Bellutti, F., Kollmann, K., Tebb, G., & Sexl, V (2016) · Oncogene · doi:10.1038/onc.2015.407 · Cited by 204

The role of CDK6 in cancer

Nebenfuehr, S., Kollmann, K., & Sexl, V. (2020) · International Journal of Cancer · doi:10.1002/ijc.33054 · Cited by 187

Dysregulated haematopoietic stem cell behaviour in myeloid leukaemogenesis

Yamashita, M., Dellorusso, P. V., Olson, O. C., & Passegue, E. A. (2020) · Nature reviews. Cancer · doi:10.1038/s41568-020-0260-3 · Cited by 197

RNA-binding protein IGF2BP3 targeting of oncogenic transcripts promotes hematopoietic progenitor proliferation

Palanichamy, J. K., Tran, T. M., Howard, J. M., Contreras, J. R., Fernando, T. R., Sterne-Weiler, T., Katzman, S. J., Toloue, M., Yan, W., Basso, G., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci80046 · Cited by 171

Targeting CDK6 in cancer: State of the art and new insights

Tadesse, S., Yu, M., Kumarasiri, M., Le, B. T., & Wang, S. (2015) · Cell Cycle · doi:10.1080/15384101.2015.1084445 · Cited by 168

LKB1, Salt-Inducible Kinases, and MEF2C Are Linked Dependencies in Acute Myeloid Leukemia

Tarumoto, Y., Lu, B., Somerville, T. D. D., Huang, Y., Milazzo, J. P., Wu, X., Klingbeil, O., Demerdash, O. E., Shi, J., & Vakoc, C. R. (2018) · Molecular Cell · doi:10.1016/j.molcel.2018.02.011 · Cited by 154

Palbociclib treatment of FLT3-ITD+ AML cells uncovers a kinase-dependent transcriptional regulation of FLT3 and PIM1 by CDK6

Uras, I. Z., Walter, G. J., Scheicher, R., Bellutti, F., Prchal‐Murphy, M., Tigan, A.-S., Valent, P., Heidel, F. H., Kubicek, S., Scholl, C., et al. (2016) · Blood · doi:10.1182/blood-2015-11-683581 · Cited by 138

miR-22 has a potent anti-tumour role with therapeutic potential in acute myeloid leukaemia

Jiang, X., Hu, C., Arnovitz, S., Bugno, J., Yu, M., Zuo, Z., Chen, P., Huang, H., Ulrich, B. C., Gurbuxani, S. K., et al. (2016) · Nature Communications · doi:10.1038/ncomms11452 · Cited by 143

Synergistic targeting of FLT3 mutations in AML via combined menin-MLL and FLT3 inhibition

Dzama, M. M., Steiner, M., Rausch, J., Sasca, D., Schönfeld, J., Kunz, K., Taubert, M. C., McGeehan, G. M., Chen, C.-W. D., Mupo, A., et al. (2020) · Blood · doi:10.1182/blood.2020005037 · Cited by 135

Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies

He, Y., Khan, S., Huo, Z., Lv, D., Zhang, X., Liu, X., Yuan, Y., Hromas, R., Xu, M., Zheng, G., et al. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00924-z · Cited by 126

Degree of Recruitment of DOT1L to MLL-AF9 Defines Level of H3K79 Di- and Tri-methylation on Target Genes and Transformation Potential

Kuntimaddi, A., Achille, N. J., Thorpe, J., Lokken, A. A., Singh, R., Hemenway, C. S., Adli, M., Zeleznik‐Le, N. J., & Bushweller, J. H. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.04.004 · Cited by 120

Targeting cell cycle regulators in hematologic malignancies

Aleem, E. A., & Arceci, R. J. (2015) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2015.00016 · Cited by 128

The Oncogenic Transcription Factor RUNX1/ETO Corrupts Cell Cycle Regulation to Drive Leukemic Transformation

Martinez-Soria, N., McKenzie, L., Draper, J. E., Ptasinska, A., Issa, H., Potluri, S., Blair, H. J., Pickin, A., Isa, A., Chin, P. S., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.08.015 · Cited by 115

CD93 Marks a Non-Quiescent Human Leukemia Stem Cell Population and Is Required for Development of MLL-Rearranged Acute Myeloid Leukemia

岩崎, 正., Liedtke, M., Gentles, A. J., & Cleary, M. L. (2015) · Cell stem cell · doi:10.1016/j.stem.2015.08.008 · Cited by 123

The CDK9 Inhibitor Dinaciclib Exerts Potent Apoptotic and Antitumor Effects in Preclinical Models of MLL-Rearranged Acute Myeloid Leukemia

Baker, A., Gregory, G. P., Verbrugge, I., Kats, L. M., Hilton, J. J., Vidacs, E., Lee, E. M., Lock, R. B., Zuber, J. A., Shortt, J., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-1070 · Cited by 117

Complementary activities of DOT1L and Menin inhibitors in MLL-rearranged leukemia

Dafflon, C., Craig, V. J., Méreau, H., Gräsel, J., Engstler, B. S., Hoffman, G., Nigsch, F., Gaulis, S., Barys, L., Ito, M., et al. (2016) · Leukemia · doi:10.1038/leu.2016.327 · Cited by 115

Synergistic Drug Combinations with a CDK4/6 Inhibitor in T-cell Acute Lymphoblastic Leukemia

Pikman, Y., Alexe, G., Roti, G., Conway, A. S., Furman, A. A., Lee, E. S., Place, A. E., Kim, S., Saran, C., Modiste, R., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2869 · Cited by 115

LncRNA Expression Discriminates Karyotype and Predicts Survival in B-Lymphoblastic Leukemia

Fernando, T. R., Rodriguez-Malave, N. I., Waters, E. V., Yan, W., Casero, D., Basso, G., Pigazzi, M., & Rao, D. S. (2015) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-15-0006-t · Cited by 107

Ubiquitin-dependent degradation of CDK2 drives the therapeutic differentiation of AML by targeting PRDX2

Ying, M., Shao, X., Jing, H., Liu, Y., Qi, X., Cao, J., Chen, Y., Xiang, S., Song, H., Hu, R., et al. (2018) · Blood · doi:10.1182/blood-2017-10-813139 · Cited by 105

NCAM1 (CD56) promotes leukemogenesis and confers drug resistance in AML.

Sasca, D., Szybinski, J., Schüler, A., Shah, V., Heidelberger, J. B., Haehnel, P. S., Dolnik, A., Kriege, O., Fehr, E.-M., Gebhardt, W., et al. (2019) · Blood · doi:10.1182/blood-2018-12-889725 · Cited by 93

MLL-Rearranged Acute Lymphoblastic Leukemia

Chaer, F. E., Keng, M. K., & Ballen, K. K. (2020) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-020-00582-5 · Cited by 100

Therapeutic Targeting the Cell Division Cycle 25 (CDC25) Phosphatases in Human Acute Myeloid Leukemia — The Possibility to Target Several Kinases through Inhibition of the Various CDC25 Isoforms

Brenner, A. K., Reikvam, H., Lavecchia, A., & Bruserud, Ø. (2014) · Molecules · doi:10.3390/molecules191118414 · Cited by 91

A Molecular Switch between Mammalian MLL Complexes Dictates Response to Menin–MLL Inhibition

Soto‐Feliciano, Y. M., Rivera, F. J. S., Perner, F., Barrows, D., Kastenhuber, E. R., Ho, Y.-J., Carroll, T., Xiong, Y., Anand, D., Soshnev, A. A., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-0416 · Cited by 85

Update on rational targeted therapy in AML

Shafer, D. A., & Grant, S. (2016) · Blood Reviews · doi:10.1016/j.blre.2016.02.001 · Cited by 79

Cyclin-dependent kinase (CDK) 9 and 4/6 inhibitors in acute myeloid leukemia (AML): a promising therapeutic approach

Lee, D. J., & Zeidner, J. F. (2019) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2019.1678583 · Cited by 78

Distinct CDK6 complexes determine tumor cell response to CDK4/6 inhibitors and degraders

Wu, X., Yang, X., Xiong, Y., Li, R., Ito, T., Ahmed, T. A., Karoulia, Z., Adamopoulos, C., Wang, H., Wang, L., et al. (2021) · Nature Cancer · doi:10.1038/s43018-021-00174-z · Cited by 75

Dual PI3K/mTOR inhibition shows antileukemic activity in MLL-rearranged acute myeloid leukemia

Sandhöfer, N., Metzeler, K. H., Rothenberg, M., Herold, T., Tiedt, S., Groiß, V., Carlet, M., Walter, G., Hinrichsen, T., Wachter, O., et al. (2014) · Leukemia · doi:10.1038/leu.2014.305 · Cited by 75

The molecular mechanics of mixed lineage leukemia

Slany, R. K. (2016) · Oncogene · doi:10.1038/onc.2016.30 · Cited by 72

CDK6 is an essential direct target of NUP98 fusion proteins in acute myeloid leukemia

Schmoellerl, J., Barbosa, I. A. M., Eder, T., Brandstoetter, T., Schmidt, L., Maurer, B., Troester, S., Pham, H. T. T., Mohanty, S., Ebner, J., et al. (2020) · Blood · doi:10.1182/blood.2019003267 · Cited by 74

ZFP36L1 promotes monocyte/macrophage differentiation by repressing CDK6

Chen, M., Dong, L., Zhang, X., Yin, X.-L., Ning, H., Shen, C., Su, R. J., Li, F., Li, S., Ma, Y., et al. (2015) · Scientific Reports · doi:10.1038/srep16229 · Cited by 71

Differentiation therapy of myeloid leukemia: four decades of development

Madan, V., & Koeffler, H. P. (2020) · Haematologica · doi:10.3324/haematol.2020.262121 · Cited by 72

Proteomic profiling reveals CDK6 upregulation as a targetable resistance mechanism for lenalidomide in multiple myeloma

Ng, Y. L. D., Ramberger, E., Bohl, S., Dolnik, A., Steinebach, C., Conrad, T., Müller, S., Popp, O., Kull, M., Haji, M., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-28515-1 · Cited by 68

RET-mediated autophagy suppression as targetable co-dependence in acute myeloid leukemia

Rudat, S., Pfaus, A., Cheng, Y., Holtmann, J., Ellegast, J. M., Bühler, C., Marcantonio, D. D., Martı́nez, E., Göllner, S., Wickenhauser, C., et al. (2018) · Leukemia · doi:10.1038/s41375-018-0102-4 · Cited by 71

Not Only Mutations Matter: Molecular Picture of Acute Myeloid Leukemia Emerging from Transcriptome Studies

Handschuh, L. (2019) · Journal of Oncology · doi:10.1155/2019/7239206 · Cited by 66

CDK6 Inhibition: A Novel Approach in AML Management

Uras, I. Z., Sexl, V., & Kollmann, K. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21072528 · Cited by 65

miR-139-5p controls translation in myeloid leukemia through EIF4G2

Emmrich, S., Engeland, F., El-Khatib, M., Henke, K., Obulkasim, A., Schöning, J., Katsman-Kuipers, J. E., Zwaan, C. M., Pich, A., Starý, J., et al. (2015) · Oncogene · doi:10.1038/onc.2015.247 · Cited by 64

Recent Advances of Cell-Cycle Inhibitor Therapies for Pediatric Cancer

Mills, C. C., Kolb, E. A., & Sampson, V. B. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-2066 · Cited by 59

MLL-AF9 initiates transformation from fast-proliferating myeloid progenitors

Chen, X., Burkhardt, D. B., Hartman, A. A., Hu, X., Eastman, A. E., Sun, C., Wang, X., Zhong, M., Krishnaswamy, S., & Guo, S. (2019) · Nature Communications · doi:10.1038/s41467-019-13666-5 · Cited by 58

Long noncoding RNA HOTAIR promotes the self-renewal of leukemia stem cells through epigenetic silencing of p15.

Gao, S.-M., Zhou, B., Li, H.-Y., Huang, X., Wu, Y.-F., Xing, C.-Y., Yu, X.-Z., & Ji, Y.-H. (2018) · Experimental Hematology · doi:10.1016/j.exphem.2018.08.005 · Cited by 59

IKAROS and MENIN coordinate therapeutically actionable leukemogenic gene expression in MLL-r acute myeloid leukemia

Aubrey, B. J., Cutler, J. A., Bourgeois, W., Donovan, K. A., Gu, S. S., Hatton, C., Perlee, S. C., Perner, F., Rahnamoun, H., Theall, A. C. P., et al. (2022) · Nature Cancer · doi:10.1038/s43018-022-00366-1 · Cited by 58

RNA-Binding Proteins in Acute Leukemias

Schuschel, K., Helwig, M., Hüttelmaier, S., Heckl, D., Klusmann, J., & Hoell, J. I. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21103409 · Cited by 57

Functional Genomic Analysis of CDK4 and CDK6 Gene Dependency across Human Cancer Cell Lines

Zhang, Z., Golomb, L., & Meyerson, M. M. (2022) · Cancer Research · doi:10.1158/0008-5472.can-21-2428 · Cited by 57

Targeting protein–protein interactions in hematologic malignancies: still a challenge or a great opportunity for future therapies?

Cierpicki, T., & Grembecka, J. (2015) · Immunological Reviews · doi:10.1111/imr.12244 · Cited by 53

Targeting cell cycle and apoptosis to overcome chemotherapy resistance in acute myeloid leukemia

Ling, V., Straube, J., Godfrey, W. A., Haldar, R., Janardhanan, Y., Cooper, L. T., Bruedigam, C., Cooper, E., Shirazi, P. T., Jacquelin, S., et al. (2022) · Leukemia · doi:10.1038/s41375-022-01755-2 · Cited by 49

Long non-coding RNAs defining major subtypes of B cell precursor acute lymphoblastic leukemia

James, A. R., Schroeder, M. P., Neumann, M., Bastian, L., Eckert, C., Gökbuget, N., Tanchez, J. O., Schlee, C., Isaakidis, K., Schwartz, S., et al. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0692-3 · Cited by 50

H19 derived microRNA-675 regulates cell proliferation and migration through CDK6 in glioma.

Li, C., Lei, B., Huang, S., Zheng, M., Liu, Z., Li, Z., & Deng, Y. (2015) · Europe PMC (PubMed Central) · Cited by 48

CDK4/6 and MAPK—Crosstalk as Opportunity for Cancer Treatment

Scheiblecker, L., Kollmann, K., & Sexl, V. (2020) · Pharmaceuticals · doi:10.3390/ph13120418 · Cited by 48

Inducible deletion of CDK4 and CDK6 – deciphering CDK4/6 inhibitor effects in the hematopoietic system

Maurer, B., Brandstoetter, T., Kollmann, S., Sexl, V., & Prchal‐Murphy, M. (2020) · Haematologica · doi:10.3324/haematol.2020.256313 · Cited by 48

Cell cycle regulation and hematologic malignancies

Dai, Y., Jin, F., Wu, W., & Kumar, S. K. (2019) · Blood Science · doi:10.1097/bs9.0000000000000009 · Cited by 46

CDKI-73: an orally bioavailable and highly efficacious CDK9 inhibitor against acute myeloid leukemia

Rahaman, M. H., Yu, Y., Zhong, L., Adams, J., Lam, F., Li, P., Noll, B., Milne, R. W., Peng, J., & Wang, S. (2018) · Investigational New Drugs · doi:10.1007/s10637-018-0661-2 · Cited by 42

An essential pathway links FLT3-ITD, HCK and CDK6 in acute myeloid leukemia

Lopez, S., Voisset, E., Tisserand, J. C., Mosca, C., Prébet, T., Santamarı́a, D., Dubreuil, P. C., & Sepulveda, P. D. (2016) · Oncotarget · doi:10.18632/oncotarget.9965 · Cited by 39

Transcriptional activation by MLL fusion proteins in leukemogenesis.

Yokoyama, A. (2017) · Experimental Hematology · doi:10.1016/j.exphem.2016.10.014 · Cited by 35

CircSPI1 acts as an oncogene in acute myeloid leukemia through antagonizing SPI1 and interacting with microRNAs

Wang, X., Jin, P., Zhang, Y., & Wang, K. (2021) · Cell Death and Disease · doi:10.1038/s41419-021-03566-2 · Cited by 33

The IRX1/HOXA connection: insights into a novel t(4;11)- specific cancer mechanism

Kühn, A., Löscher, D., & Marschalek, R. (2016) · Oncotarget · doi:10.18632/oncotarget.9241 · Cited by 33

The RUNX1/RUNX1T1 network: translating insights into therapeutic options

Swart, L. E., & Heidenreich, O. T. (2020) · Experimental Hematology · doi:10.1016/j.exphem.2020.11.005 · Cited by 32

Ribociclib, a Cdk4/Cdk6 kinase inhibitor, enhances glucocorticoid sensitivity in B-acute lymphoblastic leukemia (B-All)

Bortolozzi, R., Mattiuzzo, E., Trentin, L., Accordi, B., Basso, G., & Viola, G. (2018) · Biochemical Pharmacology · doi:10.1016/j.bcp.2018.01.050 · Cited by 31

miR-196b target screen reveals mechanisms maintaining leukemia stemness with therapeutic potential

Meyer, S. E., Muench, D. E., Rogers, A. M., Newkold, T. J., Orr, E., O'Brien, E. J., Perentesis, J. P., Doench, J. G., Lal, A., Morris, P. J., et al. (2018) · The Journal of Experimental Medicine · doi:10.1084/jem.20171312 · Cited by 30

Cdk6 contributes to cytoskeletal stability in erythroid cells

Uras, I. Z., Scheicher, R., Kollmann, K., Glösmann, M., Prchal‐Murphy, M., Tigan, A.-S., Fux, D. A., Altamura, S., Neves, J., Muckenthaler, M. U., et al. (2017) · Haematologica · doi:10.3324/haematol.2016.159947 · Cited by 31

CDC25A governs proliferation and differentiation of FLT3-ITD acute myeloid leukemia

Bertoli, S., Boutzen, H., David, L., Larrue, C., Vergez, F., Fernandez-Vidal, A., Yuan, L., Tamburini, J., Demur, C., Delabesse, É., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.5706 · Cited by 31

p16 promotes proliferation in cervical carcinoma cells through CDK6-HuR-IL1A axis

Li, M., Yang, J., Liu, K., Yang, J., Zhan, X., Wang, L., Shen, X., Chen, J., & Mao, Z. (2020) · Journal of Cancer · doi:10.7150/jca.35479 · Cited by 32

Deciphering the Therapeutic Resistance in Acute Myeloid Leukemia

Gurnari, C., Pagliuca, S., & Visconte, V. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21228505 · Cited by 31

Antileukemic Efficacy of BET Inhibitor in a Preclinical Mouse Model of MLL-AF4+ Infant ALL

Bardini, M., Trentin, L., Rizzo, F., Vieri, M., Savino, A. M., Castro, P. G., Fazio, G., Roon, E. H. J. V., Kerstjens, M. J., Smithers, N. N., et al. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-1123 · Cited by 29

The basic helix-loop-helix transcription factor SHARP1 is an oncogenic driver in MLL-AF6 acute myelogenous leukemia

Numata, A., Kwok, H. S., Kawasaki, A., Li, J., Zhou, Q.-L., Kerry, J., Benoukraf, T., Bararia, D., Li, F., Ballabio, E., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-03854-0 · Cited by 28

Targeting CDK6 and BCL2 Exploits the “MYB Addiction” of Ph+ Acute Lymphoblastic Leukemia

Dominici, M. D., Porazzi, P., Soliera, A. R., Mariani, S. A., Addya, S., Fortina, P. M., Peterson, L. F., Spinelli, O., Rambaldi, A., Martinelli, G., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-2644 · Cited by 27

TBP loading by AF4 through SL1 is the major rate-limiting step in MLL fusion-dependent transcription

Okuda, H., Takahashi, S., Takaori-Kondo, A., & Yokoyama, A. (2016) · Cell Cycle · doi:10.1080/15384101.2016.1222337 · Cited by 26

High rates of submicroscopic aberrations in karyotypically normal acute lymphoblastic leukemia

Othman, M. A. K., Melo, J. B., Carreira, I. M., Rinčić, M., Glaser, A., Grygalewicz, B., Gruhn, B., Wilhelm, K., Rittscher, K., Meyer, B., et al. (2015) · Molecular Cytogenetics · doi:10.1186/s13039-015-0153-4 · Cited by 26

Palbociclib can overcome mutations in cyclin dependent kinase 6 that break hydrogen bonds between the drug and the protein

Hernandez Maganhi, S., Jensen, P., Caracelli, I., Zukerman Schpector, J., Fröhling, S., & Friedman, R. (2017) · Protein Science · doi:10.1002/pro.3135 · Cited by 25

Investigational drugs targeting cyclin-dependent kinases for the treatment of cancer: an update on recent findings (2013-2016)

Giovanni, C. D., Novellino, E., Chilin, A., Lavecchia, A., & Marzaro, G. (2016) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2016.1234603 · Cited by 25

Cytarabine-induced differentiation of AML cells depends on Chk1 activation and shares the mechanism with inhibitors of DHODH and pyrimidine synthesis

Tomić, B., Smoljo, T., Lalić, H., Dembitz, V., Batinić, J., Batinić, D., Bedalov, A., & Višnjić, D. (2022) · Scientific Reports · doi:10.1038/s41598-022-15520-z · Cited by 25

Cyclin-Dependent Kinase Inhibitors in Hematological Malignancies—Current Understanding, (Pre-)Clinical Application and Promising Approaches

Richter, A., Schoenwaelder, N., Sender, S., Junghanss, C., & Maletzki, C. (2021) · Cancers · doi:10.3390/cancers13102497 · Cited by 24

Murine Models of Acute Myeloid Leukemia

Kurtz, K. J., Conneely, S. E., O'Keefe, M. B., Wohlan, K., & Rau, R. E. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.854973 · Cited by 25

ZNF521 sustains the differentiation block in MLL-rearranged acute myeloid leukemia

Germanò, G., Morello, G., Aveic, S., Pinazza, M., Minuzzo, S. A., Frasson, C., Persano, L., Bonvini, P., Viola, G., Bresolin, S., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.15387 · Cited by 21

WT1 facilitates the self-renewal of leukemia-initiating cells through the upregulation of BCL2L2: WT1-BCL2L2 axis as a new acute myeloid leukemia therapy target

Zhou, B., Jin, X.-H., Jin, W., Huang, X., Wu, Y.-F., Li, H.-Y., Zhu, W., Qin, X., Ye, H.-G., & Gao, S.-M. (2020) · Journal of Translational Medicine · doi:10.1186/s12967-020-02384-y · Cited by 27

NUP98 oncofusions in myeloid malignancies: An update on molecular mechanisms and therapeutic opportunities

Rasouli, M., Troester, S., Grebien, F., Goemans, B. F., Zwaan, C. M., & Heidenreich, O. T. (2024) · HemaSphere · doi:10.1002/hem3.70013 · Cited by 24

Distinct Responses to Menin Inhibition and Synergy with DOT1L Inhibition in KMT2A-Rearranged Acute Lymphoblastic and Myeloid Leukemia

Adriaanse, F. R. S., Schneider, P., Arentsen-Peters, S. T. C. J. M., da Fonseca, A. M. N., Stutterheim, J., Pieters, R., Zwaan, C. M., & Stam, R. W. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25116020 · Cited by 22

Emerging cell cycle inhibitors for acute myeloid leukemia

Zahr, A. A., & Borthakur, G. M. (2017) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2017.1330885 · Cited by 21

CDK6 Is a Therapeutic Target in Myelofibrosis

Dutta, A., Nath, D., Yang, Y., Le, B. T., & Mohi, G. (2021) · Cancer Research · doi:10.1158/0008-5472.can-21-0590 · Cited by 24

PROTAC-mediated CDK degradation differentially impacts cancer cell cycles due to heterogeneity in kinase dependencies

Kumarasamy, V. M., Gao, Z., Zhao, B., Jiang, B., Rubin, S. M., Burgess, K., Witkiewicz, A. K., & Knudsen, E. S. (2023) · British Journal of Cancer · doi:10.1038/s41416-023-02399-4 · Cited by 20

Targeting chromatin modifying complexes in acute myeloid leukemia

Schurer, A., Glushakow-Smith, S. G., & Gritsman, K. (2024) · Stem Cells Translational Medicine · doi:10.1093/stcltm/szae089 · Cited by 20

Differential role of Id1 in MLL-AF9-driven leukemia based on cell of origin.

Man, N., Sun, X.-J., Tan, Y., Garcia-Cao, M., Liu, F., Cheng, G.-Y., Hatlen, M. A., Xu, H.-M., Shah, R., Chastain, N., et al. (2016) · Blood · doi:10.1182/blood-2015-11-677708 · Cited by 22

Therapeutic Vulnerabilities in FLT3-Mutant AML Unmasked by Palbociclib

Uras, I. Z., Maurer, B., Nebenfuehr, S., Zojer, M., Valent, P., & Sexl, V. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19123987 · Cited by 19

CDK6 Degradation Is Counteracted by p16INK4A and p18INK4C in AML

Schmalzbauer, B. S., Thondanpallil, T., Heller, G., Schirripa, A., Sperl, C.-M., Mayer, I. M., Knab, V. M., Nebenfuehr, S., Zojer, M., Müller, A. C., et al. (2022) · Cancers · doi:10.3390/cancers14061554 · Cited by 17

HCK maintains the self-renewal of leukaemia stem cells via CDK6 in AML

Li, Z., Wang, F., Tian, X., Long, J., Ling, B., Zhang, W., Xu, J., & Liang, A. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-02007-4 · Cited by 17

Genome-wide screening identifies cell-cycle control as a synthetic lethal pathway with SRSF2P95H mutation

Xu, J. J., Chalk, A. M., Nikolić, I., Simpson, K. J., Smeets, M. F. M. A., & Walkley, C. R. (2021) · Blood Advances · doi:10.1182/bloodadvances.2021004571 · Cited by 19

NFkB is activated by multiple mechanisms in hairy cell leukemia

Nagel, S., Ehrentraut, S., Meyer, C., Kaufmann, M., Drexler, H. G., & MacLeod, R. A. F. (2015) · Genes Chromosomes and Cancer · doi:10.1002/gcc.22253 · Cited by 18

Advances in molecular characterization of pediatric acute megakaryoblastic leukemia not associated with Down syndrome; impact on therapy development

Li, J., & Kalev‐Zylinska, M. L. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1170622 · Cited by 16

Computer simulations of the signalling network in FLT3 +-acute myeloid leukaemia – indications for an optimal dosage of inhibitors against FLT3 and CDK6

Buetti‐Dinh, A., & Friedman, R. (2018) · BMC Bioinformatics · doi:10.1186/s12859-018-2145-y · Cited by 16

Palbociclib—The First of a New Class of Cell Cycle Inhibitors

Schmidt, M., & Sebastian, M. (2018) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-319-91442-8_11 · Cited by 18

Learning from mouse models of MLL fusion gene-driven acute leukemia.

Schwaller, J. (2020) · Biochimica et Biophysica Acta. Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2020.194550 · Cited by 16

Emerging therapeutic targets for the treatment of human acute myeloid leukemia (part 1) – gene transcription, cell cycle regulation, metabolism and intercellular communication

Reikvam, H., Hauge, M., Brenner, A. K., Hatfield, K. J., & Bruserud, Ø. (2015) · Expert Review of Hematology · doi:10.1586/17474086.2015.1032935 · Cited by 16

MLL fusion-driven activation ofCDK6potentiates proliferation inMLL-rearranged infant ALL

der Linden, M. V., Willekes, M., Roon, E. H. J. V., Seslija, L., Schneider, P., Pieters, R., & Stam, R. W. (2014) · Cell Cycle · doi:10.4161/cc.27757 · Cited by 51

CYC065, potential therapeutic agent for AML and MLL leukaemia

Frame, S., Saladino, C., Davis, S., Blake, D., & Zheleva, D. I. (2015) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2015.04.027 · Cited by 6

Investigation of a Novel Cyclin-Dependent-Kinase (CDK) Inhibitor Cdki-73 As an Effective Treatment Option for MLL-AML

Li, K. L., Bray, S. C. E., Iarossi, D. G., Adams, J., Zhong, L., Noll, B., Rahaman, M. H., Richmond, J., To, L. B., Lewis, I. D., et al. (2015) · Blood · doi:10.1182/blood.v126.23.1365.1365 · Cited by 6

Abstract 3886: Therapeutic potential of CDK inhibitors in MLL leukemias

Frame, S., Hogben, M., Munro, C., Blake, D., Green, S. R., & Zheleva, D. I. (2010) · Cancer Research · doi:10.1158/1538-7445.am10-3886 · Cited by 1

CDK6 Inhibition: A Novel Approach in AML Management

Uras, I. Z., Sexl, V., & Kollmann, K. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21072528 · Cited by 65